Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

tgDCC-E1A gene therapy - Targeted Genetics

Drug Profile

tgDCC-E1A gene therapy - Targeted Genetics

Alternative Names: E1A gene therapy; HER-2/neu inhibitor; LF 160519; RGG 0853

Latest Information Update: 14 Mar 2008

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Targeted Genetics
  • Developer Targeted Genetics; Targeted Genetics Corporation
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer; Head and neck cancer; Ovarian cancer

Most Recent Events

  • 14 Aug 2002 Suspended - Phase-I for Ovarian cancer in USA (Intratumoural)
  • 07 Aug 2002 Suspended - Phase-I for Ovarian cancer in Europe (Intratumoural)
  • 07 Aug 2002 Suspended - Phase-II for Head and neck cancer in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top